Abstract 5189
Background
Small cell lung cancer (SCLC) is a highly lethal disease. Recently, immunotherapy has demonstrated a benefit for a subgroup of patients beyond the second-line and in the first-line setting combined with chemotherapy. However, the majority of patients will not benefit and predictive biomarkers are urgently needed. High baseline neutrophil count (NC) and neutrophil-to-lymphocyte ratio (NLR) are unfavorable prognostic factors in SCLC and might also predict for lack of response to immunotherapy. There is data suggesting that activation of the HGF/MET pathway might contribute to the recruitment of immunosuppressor neutrophils in the tumor. Our aim was to evaluate the association between HGF serum levels (sHGF) and NC in SCLC and their impact on outcome.
Methods
Serum samples from SCLC patients were obtained before starting first-line treatment. We used the Quantikine Human HGF Immunoassay to quantify sHGF. All samples were run in duplicates. NC and NLR were obtained from blood test reports before treatment initiation. Statistical analysis was carried out using SPSS 22.0 and Prism 8.1.0. Correlation of variables was assessed by the Spearman’s correlation coefficient. Multivariate analysis was performed with the Cox regression method.
Results
Samples from 105 patients diagnosed with SCLC at our institution were included. 79.1% of the cases were male, 73.3% with extensive stage, and 31.4% had an ECOG score of ≥ 2. Median sHGF, NC and NLR were 1875.38pg/ml, 6440/µl and 5.1 respectively. Patients with baseline NLR > 4 or NC above median had worse median overall survival (mOS), with 7.9 vs 15.3 months (m) (p < 0.001) and 7.2 vs 15.3m (p < 0.001) respectively. sHGF above median values was also correlated with worse mOS (7.6 vs 12.8 m; p = 0.005). Baseline sHGF levels were positively correlated with NC (r = 0.34, p < 0.001). In the multivariate analysis for OS, sHGF and NC remained independently associated with poor outcome (HR 1.094; p = 0.001 and HR 1.18; p = 0.003 respectively).
Conclusions
Baseline HGF levels correlate with NC in SCLC, reinforcing the hypothesis of a plausible interplay between HGF/MET axis and the immune system. The role of these parameters as predictive biomarkers of response to immunotherapy in SCLC warrants further investigation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
E. Arriola: Speaker Bureau / Expert testimony: BMS; Speaker Bureau / Expert testimony: Roche; Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony: Pfizer; Speaker Bureau / Expert testimony: Lilly; Speaker Bureau / Expert testimony: AstraZeneca; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): PGDx; Travel / Accommodation / Expenses: BMS; Travel / Accommodation / Expenses: MSD; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Lilly. All authors have declared no conflicts of interest.
Resources from the same session
4085 - A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in Patients with Advanced Solid Tumors
Presenter: Anthony Tolcher
Session: Poster Display session 1
Resources:
Abstract
1054 - Safety, efficacy, and pharmacokinetic (PK) profile of cosibelimab, an anti‐PD‐L1 antibody, in patients (pts) with advanced cancers
Presenter: Philip Clingan
Session: Poster Display session 1
Resources:
Abstract
4264 - A Phase I study of tinostamustine in patients (pts) with advanced solid tumours
Presenter: Alain Mita
Session: Poster Display session 1
Resources:
Abstract
3811 - Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors
Presenter: Santiago Ponce Aix
Session: Poster Display session 1
Resources:
Abstract
1311 - A phase I study of varlitinib (VAR; ASLAN001) an oral pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI chemotherapy in advanced solid tumors
Presenter: Aaron Tan
Session: Poster Display session 1
Resources:
Abstract
3482 - Phase I study of lapatinib and trametinib in patients with KRAS mutant colorectal, non-small cell lung and pancreatic cancer
Presenter: Sanne Huijberts
Session: Poster Display session 1
Resources:
Abstract
4749 - Pharmacokinetic (PK) and updated survival data from the Canadian Cancer Trials Group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy
Presenter: Desiree Hao
Session: Poster Display session 1
Resources:
Abstract
4530 - A Phase 2a clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumors harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification
Presenter: Funda Meric-Bernstam
Session: Poster Display session 1
Resources:
Abstract
4280 - Updated Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Tumors: Integrated Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster Display session 1
Resources:
Abstract
6144 - An international randomized cross-over bio-equivalence study of oral paclitaxel + HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumors
Presenter: Christopher Jackson
Session: Poster Display session 1
Resources:
Abstract